Found: 51
Select item for more details and to access through your institution.
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. E260, doi. 10.1002/ajh.25908
- By:
- Publication type:
- Article
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 7, p. E159, doi. 10.1002/ajh.25102
- By:
- Publication type:
- Article
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. 617, doi. 10.1002/ajh.24362
- By:
- Publication type:
- Article
Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 10, p. 910, doi. 10.1002/ajh.24120
- By:
- Publication type:
- Article
Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 10, p. 897, doi. 10.1002/ajh.22104
- By:
- Publication type:
- Article
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 6, p. 523, doi. 10.1002/ajh.22020
- By:
- Publication type:
- Article
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 12, p. 960, doi. 10.1002/ajh.21871
- By:
- Publication type:
- Article
Complete remission with brentuximab vedotin in a case of primary cutaneous gamma‐delta T‐cell lymphoma relapsed after allogeneic stem cell transplantation.
- Published in:
- International Journal of Dermatology, 2021, v. 60, n. 6, p. 778, doi. 10.1111/ijd.15393
- By:
- Publication type:
- Article
Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2018, v. 10, n. 1, p. 1, doi. 10.4084/MJHID.2018.001
- By:
- Publication type:
- Article
Flow Cytometry Assessment of CD26<sup>+</sup> Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.
- Published in:
- Cytometry. Part B, 2019, v. 96, n. 4, p. 294, doi. 10.1002/cyto.b.21764
- By:
- Publication type:
- Article
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 3, p. 286, doi. 10.1111/ejh.13436
- By:
- Publication type:
- Article
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.672287
- By:
- Publication type:
- Article
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. 1, doi. 10.3389/fonc.2020.00883
- By:
- Publication type:
- Article
Myeloma plasma cell Multiparametric Flow Cytometry (MFC) detection in autograft products of Newly Diagnosed Multiple Myeloma (NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e172, doi. 10.1016/j.clml.2019.09.289
- By:
- Publication type:
- Article
Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e172, doi. 10.1016/j.clml.2019.09.288
- By:
- Publication type:
- Article
Outcome of MDS, MDS/MPN Patients Aged <65 Treated with Hypomethylating Agents as a Bridge to Transplant in a Single Tertiary-Care Italian Center.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S346, doi. 10.1016/j.clml.2019.07.354
- By:
- Publication type:
- Article
Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S313, doi. 10.1016/j.clml.2017.07.114
- By:
- Publication type:
- Article
Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e85, doi. 10.1016/j.clml.2017.03.154
- By:
- Publication type:
- Article
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 6, p. 1, doi. 10.1038/s41408-020-0333-2
- By:
- Publication type:
- Article
Toxoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in Allogeneic Transplantation.
- Published in:
- 2021
- By:
- Publication type:
- Letter
The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 5, p. 653, doi. 10.1111/j.1365-2141.2006.06365.x
- By:
- Publication type:
- Article
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 11, p. 1527, doi. 10.1080/0284186X.2021.1971292
- By:
- Publication type:
- Article
Severe Hypoxia Defines Heterogeneity and Selects Highly Immature Progenitors Within Clonal Erythroleukemia Cells.
- Published in:
- Stem Cells, 2007, v. 25, n. 5, p. 1119, doi. 10.1634/stemcells.2006-0637
- By:
- Publication type:
- Article
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 559, doi. 10.1111/bjh.17890
- By:
- Publication type:
- Article
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 2, p. 267, doi. 10.1111/bjh.14553
- By:
- Publication type:
- Article
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study.
- Published in:
- Drugs & Aging, 2013, v. 30, n. 8, p. 629, doi. 10.1007/s40266-013-0088-6
- By:
- Publication type:
- Article
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-019-0815-5
- By:
- Publication type:
- Article
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 7, p. 1002, doi. 10.1002/cncr.28522
- By:
- Publication type:
- Article
Evaluation of residual CD34<sup>+</sup>Ph<sup>+</sup> progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 21, p. 5265, doi. 10.1002/cncr.27506
- By:
- Publication type:
- Article
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes: A Retrospective Study of 74 Patients Enrolled in an Italian Named Patient Program.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 6, p. 1485, doi. 10.1002/cncr.24894
- By:
- Publication type:
- Article
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients.
- Published in:
- Leukemia Research & Treatment, 2012, p. 1, doi. 10.1155/2012/150651
- By:
- Publication type:
- Article
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.839915
- By:
- Publication type:
- Article
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.835563
- By:
- Publication type:
- Article
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.739171
- By:
- Publication type:
- Article
Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 4, p. 607, doi. 10.1002/hon.2765
- By:
- Publication type:
- Article
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
- Published in:
- Hematological Oncology, 2013, v. 31, n. 2, p. 363, doi. 10.1002/hon.2020
- By:
- Publication type:
- Article
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 16, p. 5267, doi. 10.3390/jcm12165267
- By:
- Publication type:
- Article
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3692, doi. 10.3390/jcm9113692
- By:
- Publication type:
- Article
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 427, doi. 10.1007/s00277-023-05556-0
- By:
- Publication type:
- Article
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2005, doi. 10.1007/s00277-020-04392-w
- By:
- Publication type:
- Article
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
- Published in:
- Annals of Hematology, 2013, v. 92, n. 2, p. 179, doi. 10.1007/s00277-012-1591-2
- By:
- Publication type:
- Article
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
- Published in:
- Annals of Hematology, 2010, v. 89, n. 2, p. 185, doi. 10.1007/s00277-009-0793-8
- By:
- Publication type:
- Article
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
- Published in:
- Annals of Hematology, 2005, v. 84, p. 54, doi. 10.1007/s00277-005-0006-z
- By:
- Publication type:
- Article
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.
- Published in:
- Frontiers in Oncology, 2018, p. 1, doi. 10.3389/fonc.2018.00194
- By:
- Publication type:
- Article
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 823, doi. 10.1007/s11523-021-00831-4
- By:
- Publication type:
- Article